BACKGROUND: There is no consensus on the definition of a hot, nonblue sentinel lymph node (SLN), despite the widespread use of radiocolloid in SLN mapping. METHODS: A retrospective review of 592 patients with malignant melanoma who underwent SLN mapping was performed. Ex vivo SLN counts and nodal bed counts were obtained by using a gamma probe. The size of each metastatic deposit in an SLN was defined as macrometastases (>2 mm), micrometastases (< or =2 mm), a cluster of cells, or isolated melanoma cells. RESULTS: A total of 1175 SLNs (SLN(-), n = 1041; SLN(+), n = 134) were evaluated. The mean SLN count/bed counts were SLN(-), 322 +/- 980 and SLN(+), 450 +/- 910 (not significant [NS]) (>2 mm, 270 +/- 792 [NS]; < or =2 mm, 446 +/- 693 [NS]; isolated melanoma cells/cluster of cells, 677 +/- 1189 [P =.036]). Overall, 16 (1.4%) of the SLNs collected had an overall ratio of < or =2. This included two positive SLNs (1.5%), both of which contained macrometastatic disease. Forty-seven positive nodal basins had at least one negative SLN. The hottest SLNs in these basins were negative for metastatic disease in nine cases (19.1%). In one basin (2.1%), the positive SLN count was <10% of the hottest lymph node count. CONCLUSIONS: Removal of lymph nodes until the bed count is 10% of the hottest lymph node will remove 98% of positive SLNs. Lymph node tumor burden influences radioactive counts.
BACKGROUND: There is no consensus on the definition of a hot, nonblue sentinel lymph node (SLN), despite the widespread use of radiocolloid in SLN mapping. METHODS: A retrospective review of 592 patients with malignant melanoma who underwent SLN mapping was performed. Ex vivo SLN counts and nodal bed counts were obtained by using a gamma probe. The size of each metastatic deposit in an SLN was defined as macrometastases (>2 mm), micrometastases (< or =2 mm), a cluster of cells, or isolated melanoma cells. RESULTS: A total of 1175 SLNs (SLN(-), n = 1041; SLN(+), n = 134) were evaluated. The mean SLN count/bed counts were SLN(-), 322 +/- 980 and SLN(+), 450 +/- 910 (not significant [NS]) (>2 mm, 270 +/- 792 [NS]; < or =2 mm, 446 +/- 693 [NS]; isolated melanoma cells/cluster of cells, 677 +/- 1189 [P =.036]). Overall, 16 (1.4%) of the SLNs collected had an overall ratio of < or =2. This included two positive SLNs (1.5%), both of which contained macrometastatic disease. Forty-seven positive nodal basins had at least one negative SLN. The hottest SLNs in these basins were negative for metastatic disease in nine cases (19.1%). In one basin (2.1%), the positive SLN count was <10% of the hottest lymph node count. CONCLUSIONS: Removal of lymph nodes until the bed count is 10% of the hottest lymph node will remove 98% of positive SLNs. Lymph node tumor burden influences radioactive counts.
Authors: Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin Journal: World J Surg Oncol Date: 2009-01-27 Impact factor: 2.754
Authors: Edward L Jones; Teresa S Jones; Nathan W Pearlman; Dexiang Gao; Robert Stovall; Csaba Gajdos; Nicole Kounalakis; Rene Gonzalez; Karl D Lewis; William A Robinson; Martin D McCarter Journal: JAMA Surg Date: 2013-05 Impact factor: 14.766
Authors: M Ankersmit; O S Hoekstra; A van Lingen; E Bloemena; M A J M Jacobs; D J Vugts; H J Bonjer; G A M S van Dongen; W J H J Meijerink Journal: Eur J Nucl Med Mol Imaging Date: 2019-02-23 Impact factor: 9.236
Authors: Feng Chen; Brian Madajewski; Kai Ma; Daniella Karassawa Zanoni; Hilda Stambuk; Melik Z Turker; Sébastien Monette; Li Zhang; Barney Yoo; Peiming Chen; Richard J C Meester; Sander de Jonge; Pablo Montero; Evan Phillips; Thomas P Quinn; Mithat Gönen; Sonia Sequeira; Elisa de Stanchina; Pat Zanzonico; Ulrich Wiesner; Snehal G Patel; Michelle S Bradbury Journal: Sci Adv Date: 2019-12-04 Impact factor: 14.136
Authors: Daniella Karassawa Zanoni; Hilda E Stambuk; Brian Madajewski; Pablo H Montero; Danielli Matsuura; Klaus J Busam; Kai Ma; Melik Z Turker; Sonia Sequeira; Mithat Gonen; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury; Snehal G Patel Journal: JAMA Netw Open Date: 2021-03-01
Authors: L W T Alkureishi; Z Burak; J A Alvarez; J Ballinger; A Bilde; A J Britten; L Calabrese; C Chiesa; A Chiti; R de Bree; H W Gray; K Hunter; A F Kovacs; M Lassmann; C R Leemans; G Mamelle; M McGurk; J Mortensen; T Poli; T Shoaib; P Sloan; J A Sorensen; S J Stoeckli; J B Thomsen; G Trifiro; J Werner; G L Ross Journal: Ann Surg Oncol Date: 2009-11 Impact factor: 5.344
Authors: Lee W T Alkureishi; Zeynep Burak; Julio A Alvarez; James Ballinger; Anders Bilde; Alan J Britten; Luca Calabrese; Carlo Chiesa; Arturo Chiti; Remco de Bree; Harry W Gray; Keith Hunter; Adorjan F Kovacs; Michael Lassmann; C Rene Leemans; Gerard Mamelle; Mark McGurk; Jann Mortensen; Tito Poli; Taimur Shoaib; Philip Sloan; Jens A Sorensen; Sandro J Stoeckli; Jorn B Thomsen; Giusepe Trifiro; Jochen Werner; Gary L Ross Journal: Eur J Nucl Med Mol Imaging Date: 2009-11 Impact factor: 9.236